# Follicular Lymphoma

Manage follicular lymphoma by confirming grade and excluding transformation, staging with FDG PET/CT, reserving therapy for clinically consequential disease, and tailoring relapse treatment to timing, prior exposure, refractoriness, fitness, and planned cellular or T-cell–engaging therapy.

**Clinical question:** How should physicians stage, risk-stratify, treat, and manage relapse in follicular lymphoma?

Updated: 2026-08-21T02:13:38.373936+00:00

## What matters in practice
- Obtain FDG PET/CT for pretreatment staging and response assessment; it is more sensitive than standard CT and can identify a lesion requiring biopsy when transformation is suspected. [4][19]
- Do not use baseline SUVmax alone to diagnose histologic transformation; prospective GALLIUM data did not corroborate its predictive value. [4][24]
- Observation remains an acceptable initial strategy for low-grade follicular lymphoma when disease does not require immediate treatment. [10]
- Progression within 24 months after first-line treatment defines early symptomatic progression (POD24) and should prompt a distinct relapse assessment and treatment strategy. [7][12]
- For rituximab-refractory early relapse, obinutuzumab-bendamustine is an option, but avoid bendamustine when subsequent T-cell–engaging therapy is anticipated because of prolonged immunosuppression. [12]

## Confirm follicular lymphoma and identify disease requiring a different pathway

The first management decision is whether the biopsy establishes indolent FL or suggests grade 3B disease or transformation.

Use an adequate tissue specimen that permits assessment of nodal architecture, cytology, and immunophenotype. Excisional biopsy is preferred when feasible because architecture may be necessary to establish lymphoma in lesions composed of well-differentiated lymphocytes; needle samples can provide insufficient architectural information. [23]

Separate grade 1-2 and grade 3A FL from grade 3B FL at diagnosis because grade 3B was excluded from a major frontline FL trial and should not automatically be managed under an indolent-FL treatment framework. [17] Grade assignment is clinically consequential, but reproducibility between low-grade FL and grade 3A can be challenging. [5]

At progression, do not assume recurrent indolent FL when there is discordant clinical behavior or a new highly FDG-avid site. Transformed indolent lymphoma can present on PET/CT as newly increased nodal avidity or new FDG-avid lesions in other organs; biopsy the most clinically suspicious accessible lesion before selecting therapy intended for relapsed indolent FL. [19]
- Escalate to repeat tissue diagnosis when a new lesion or pace of disease is discordant with prior indolent behavior. [19]
- Do not infer transformation from SUVmax alone; high baseline SUVmax did not predict transformation in the prospective GALLIUM analysis. [4][24]
- If transformation is identified, redirect management to the transformed lymphoma rather than applying a routine FL relapse sequence. [19]

*Biopsy and imaging findings that change the follicular lymphoma management pathway. [4][5][17][19][23][24]*

| Finding | Interpretation | Next action |
| --- | --- | --- |
| Limited or nondiagnostic needle tissue | Architectural assessment may be inadequate for lymphoma confirmation or grading. [23] | Obtain excisional tissue when feasible. [23] |
| Grade 1-2 or grade 3A FL | Usually follows an indolent-FL treatment framework, with grade 3A classification requiring careful pathology review. [5][17] | Stage and determine whether disease requires treatment. [4][10] |
| Grade 3B FL | Not represented in a major frontline trial of previously untreated FL. [17] | Use a separate aggressive-lymphoma-oriented treatment assessment rather than extrapolating directly from indolent-FL trial populations. [17] |
| New or markedly more FDG-avid lesion at relapse | May indicate histologic transformation, but avidity alone is not diagnostic. [19][24] | Biopsy the suspicious lesion before choosing relapse therapy. [19] |

## Use PET/CT to establish extent and select a biopsy target

Staging should distinguish truly limited disease from disseminated FL and identify sites that merit histologic reassessment.

Use FDG PET/CT as the preferred imaging modality for staging and response assessment in FL. PET/CT is more sensitive than standard CT, can improve identification of truly limited-stage disease, and helps distinguish viable tumor from residual fibrotic tissue after treatment. [4]

Do not rely on PET/CT to exclude marrow involvement. PET/CT has relatively low sensitivity for FL marrow disease, so a negative scan does not establish marrow-negative disease when marrow status would alter staging or management. [2]

For patients being considered for limited-stage treatment, rigorously establish stage with imaging and bone marrow biopsy. In PET-era outcome data, patients staged with marrow biopsy plus CT or PET/CT had superior progression-free survival compared with less rigorously staged cohorts, supporting careful confirmation before labeling disease as stage I/II. [6]
- Use baseline PET/CT to document disease distribution before systemic treatment and as the comparator for metabolic response assessment. [4]
- Use PET/CT to identify an accessible, biologically concerning lesion for biopsy rather than treating SUVmax as a transformation test. [4][19][24]
- When apparent localized disease would lead to a localized treatment plan, add bone marrow biopsy because PET/CT may miss marrow involvement. [2][6]

### Prognosis versus treatment indication

Calculate FLIPI at diagnosis for prognostic discussion, but do not use FLIPI alone as a treatment trigger. FLIPI was developed to predict survival at diagnosis, while treatment timing remains driven by the clinical burden and consequences of disease. [1][10]

A negative end-of-treatment PET/CT is a strong independent prognostic marker for progression-free and overall survival in high-tumor-burden FL, but current evidence does not establish PET-guided treatment escalation as routine care. [4]

*Practical role of imaging and marrow assessment in follicular lymphoma. [2][4][6][19]*

| Clinical question | Preferred assessment | Decision consequence |
| --- | --- | --- |
| Initial extent of nodal and extranodal disease | FDG PET/CT. [4] | Improves staging sensitivity and identification of truly limited disease. [4] |
| Is apparent stage I/II truly localized? | PET/CT plus bone marrow biopsy when stage determination will affect management. [2][6] | Avoids understaging caused by PET-insensitive marrow involvement. [2][6] |
| Could progression represent transformation? | PET/CT followed by biopsy of the most suspicious accessible lesion. [19] | Avoids treating transformed lymphoma as routine indolent FL relapse. [19] |
| Did treatment eradicate metabolically active disease? | End-of-treatment PET/CT. [4] | A negative scan is prognostic, but not an established mandate for PET-directed escalation. [4] |

## Treat clinical disease burden, not the diagnosis alone

Newly diagnosed FL does not require immediate systemic therapy in every patient.

Observation remains an acceptable initial strategy for low-grade FL when disease is not creating a clinical indication for therapy. This approach avoids immediate treatment toxicity in a disease course where patients commonly require multiple treatments over time. [10][1]

When initiating systemic frontline treatment, select the regimen according to disease burden, treatment goals, comorbidity, and anticipated long-term sequence rather than assuming one induction strategy fits all patients. A phase III trial compared rituximab-lenalidomide with rituximab-chemotherapy followed by rituximab in previously untreated FL and evaluated complete response, progression-free survival, time to next treatment, overall survival, adverse events, and quality of life. [17]

For patients responding to rituximab-containing chemotherapy, rituximab maintenance for 2 years improved progression-free survival in high-tumor-burden FL in the PRIMA randomized trial; long-term follow-up reported that approximately half of maintenance-treated patients remained progression-free at 10 years. [1] Balance this disease-control benefit against continued anti-CD20 exposure and the patient's anticipated subsequent treatment needs.
- Choose observation when low-grade disease does not require immediate intervention. [10]
- Before treating, document PET/CT baseline disease sites so post-treatment metabolic response can be interpreted. [4]
- Discuss 2-year rituximab maintenance after response to rituximab-chemotherapy as a progression-free-survival strategy, not as a proven requirement for every responding patient. [1][15]

*Frontline management decisions in follicular lymphoma. [1][4][10][15][17]*

| Clinical state | Management approach | Key tradeoff |
| --- | --- | --- |
| Low-grade FL without an immediate clinical treatment indication | Active observation is acceptable. [10] | Defers treatment toxicity, while requiring surveillance for a new treatment indication. [10][1] |
| Disease selected for systemic frontline therapy | Establish pretreatment PET/CT and choose a systemic strategy based on patient and disease factors. [4][17] | Treatment selection must preserve future options in a disease commonly requiring repeated therapy. [1] |
| Response after rituximab-chemotherapy | Consider rituximab maintenance for 2 years. [1] | Improves progression-free survival; long-term disease control must be balanced against ongoing anti-CD20 exposure. [1][15] |

## Classify relapse by timing, anti-CD20 sensitivity, prior therapy, and treatment sequence

At each relapse, reassess histology and determine whether progression meets the POD24 high-risk pattern.

Define early symptomatic progression as relapse within 24 months after completion of first-line therapy (POD24). This interval identifies a clinically important high-risk subgroup and should trigger reassessment for transformation, prior treatment refractoriness, fitness for intensive strategies, and suitability for T-cell–engaging therapy or cellular therapy sequencing. [7][12]

For rituximab-refractory FL with early progression, obinutuzumab-bendamustine is an evidence-supported option. However, if a T-cell–engaging therapy is anticipated later, avoid bendamustine because its long-term immunosuppression may compromise that sequence. [12]

For lenalidomide-naive early relapse, rituximab-lenalidomide is an option. ESMO also lists rituximab-lenalidomide-tafasitamab and rituximab-lenalidomide-epcoritamab for lenalidomide-naive early progression; the epcoritamab combination is FDA approved but not EMA approved. [12]

For younger fit patients with early POD and chemosensitive relapse, consider autologous stem-cell transplantation as consolidation. This requires establishing chemosensitivity and excluding transformed disease before proceeding. [12][19]
- Biopsy a suspicious relapse site before selecting an indolent-FL regimen when transformation is plausible. [19]
- Record whether relapse occurred within or after 24 months of first-line completion; this timing changes the risk discussion and second-line strategy. [7][12]
- Document prior lenalidomide and bendamustine exposure before choosing a second-line regimen. [12][13]
- Avoid bendamustine when preserving a future T-cell–engaging therapy pathway is a priority. [12]

### Later-line treatment sequencing

At third line and beyond, treatment selection should be explicitly sequenced from prior exposure. Common choices include rituximab-lenalidomide when not previously used or rituximab plus chemotherapy when rituximab-lenalidomide was used previously; chemotherapy may include rituximab-bendamustine in a patient fit for treatment without prior bendamustine exposure. [13]

Mosunetuzumab-lenalidomide is being evaluated after at least one systemic line against rituximab-lenalidomide, with progression-free survival by Lugano criteria as the primary endpoint. Do not substitute trial design for established comparative efficacy when counseling patients about available standard options. [18]
- Use prior lenalidomide exposure to decide whether a rituximab-lenalidomide-based approach remains available. [12][13]
- Use prior bendamustine exposure and the anticipated use of T-cell–engaging therapy to avoid an unfavorable immunosuppressive sequence. [12]

*Second-line decision framework for relapsed follicular lymphoma. [7][12][13][19]*

| Relapse pattern | Actionable discriminator | Management direction |
| --- | --- | --- |
| New suspicious lesion or discordant relapse behavior | Possible transformation on PET/CT. [19] | Biopsy the most suspicious accessible lesion before treating as indolent FL. [19] |
| Symptomatic relapse within 24 months of first-line completion | POD24. [7][12] | Use an early-progression strategy based on refractoriness, prior therapy, fitness, and future cellular or T-cell–engaging options. [12] |
| Rituximab-refractory early relapse | Anti-CD20 refractoriness. [12] | Obinutuzumab-bendamustine is an option; avoid bendamustine if future T-cell–engaging therapy is planned. [12] |
| Lenalidomide-naive early relapse | No prior lenalidomide exposure. [12] | Rituximab-lenalidomide is an option; specified triplet approaches are additional options in the ESMO pathway. [12] |
| Younger, fit, chemosensitive early relapse | Response to salvage therapy and transplant fitness. [12] | Consider autologous stem-cell transplantation consolidation. [12] |

## Use follow-up to detect clinically meaningful progression and transformation

Surveillance should focus on a new indication for therapy, treatment response, and evidence that relapse biology has changed.

After treatment, use PET/CT response assessment to distinguish metabolically active disease from residual fibrotic tissue. A negative PET/CT after treatment has strong independent prognostic value for progression-free and overall survival, particularly in high-tumor-burden FL. [4]

Do not use interim PET/CT as a routine treatment-adaptation tool. Although interim PET may add prognostic information beyond FLIPI and FLIPI-2, its role in directing therapy remains unsettled. [20]

At clinical or radiographic progression, repeat PET/CT when the pattern could alter management and biopsy a newly or disproportionately avid lesion. The key surveillance failure is missing transformation and continuing an indolent-FL pathway without renewed tissue confirmation. [19]
- Interpret residual masses with PET/CT rather than anatomic imaging alone when determining whether viable lymphoma remains. [4]
- Use a negative end-of-treatment PET/CT for prognosis, not as a standalone reason to escalate therapy. [4]
- At relapse, compare the distribution and avidity of lesions with baseline imaging and obtain tissue from a concerning site. [19]

*Response and progression monitoring actions in follicular lymphoma. [4][19][20]*

| Monitoring event | Test or action | Interpretation |
| --- | --- | --- |
| End of systemic treatment | FDG PET/CT. [4] | Separates viable tumor from residual fibrosis; PET negativity is prognostic. [4] |
| Interim treatment assessment | Interim PET/CT only when a specific clinical question justifies it. [20] | Potential prognostic value does not establish routine PET-directed treatment modification. [20] |
| New progression pattern | PET/CT and biopsy of the most suspicious accessible site. [19] | New or increased FDG avidity can signal transformation and changes the therapeutic pathway. [19] |

## References
1. Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups | Blood Cancer Journal — www.nature.com — https://www.nature.com/articles/s41408-020-00340-z
2. FDG PET-CT in follicular lymphoma: a case-based evidence ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S000649712035268X
3. Pathology Consultation on Intermediate-to-Large B-Cell ... — academic.oup.com — https://academic.oup.com/ajcp/article-pdf/141/3/305/24996620/ajcpath141-0305.pdf
4. Is it time for PET-guided therapy in follicular lymphoma? — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0006497121013483
5. Evaluating Novel PET-CT Functional Parameters TLG and ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S2152265019319962
6. Outcomes of stage I/II follicular lymphoma in the PET era — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S2473952920318425
7. The POD24 challenge: where do we go from here for early ... — ashpublications.org — https://ashpublications.org/hematology/article/2024/1/301/526148/The-POD24-challenge-where-do-we-go-from-here-for
8. The treatment of marginal zone lymphoma | Blood — ashpublications.org — https://ashpublications.org/blood/article/147/2/115/546195/The-treatment-of-marginal-zone-lymphoma
9. Current landscape of frontline and relapsed follicular ... — ashpublications.org — https://ashpublications.org/bloodneoplasia/article/2/4/100131/537831/Current-landscape-of-frontline-and-relapsed
10. Is watch and wait still acceptable for patients with low-grade ... — ashpublications.org — https://ashpublications.org/blood/article/127/23/2804/35265/Is-watch-and-wait-still-acceptable-for-patients
11. Podcast: Modern Management of Mantle Cell Lymphoma — ascopubs.org — https://ascopubs.org/do/modern-management-mantle-cell-lymphoma-biological-risk-btki-and-beyond
12. Follicular Lymphoma: Relapsed or Refractory Disease Management in Second Line — www.esmo.org — https://www.esmo.org/guidelines/living-guidelines/esmo-living-guideline-lymphomas/follicular-lymphoma-fl/follicular-lymphoma-disease-management/relapsed-refractory-follicular-lymphoma/follicular-lymphoma-relapsed-or-refractory-disease-management-in-second-line
13. 3 Committee discussion | Mosunetuzumab for treating relapsed or refractory follicular lymphoma | Guidance | NICE — www.nice.org.uk — https://www.nice.org.uk/guidance/ta892/chapter/3-Committee-discussion
14. national institute for health and — www.nice.org.uk — https://www.nice.org.uk/guidance/ta137/documents/roche-products-limited2
15. Rituximab for the first-line maintenance treatment of ... — www.nice.org.uk — https://www.nice.org.uk/guidance/ta226/resources/rituximab-for-the-firstline-maintenance-treatment-of-follicular-nonhodgkins-lymphoma-pdf-82600313486533
16. Confidential: not for release — www.nice.org.uk — https://www.nice.org.uk/guidance/ta137/documents/lymphoma-follicular-nonhodgkins-rituximab-evidence-review-group-report2
17. Study Details | NCT01650701 | A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma | ClinicalTrials.gov — clinicaltrials.gov — https://clinicaltrials.gov/study/NCT01650701
18. Study Details | NCT04712097 | A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma | ClinicalTrials.gov — clinicaltrials.gov — https://clinicaltrials.gov/study/NCT04712097
19. 6 Imaging in follicular NHL — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1521692611000120
20. Prognostic value of interim PET-CT in follicular lymphoma — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0025775326000618
21. Does increased PET avidity predict follicular lymphoma ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0006497125063529
22. Utility of FDG-PET in predicting the histology of relapsed or ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2473952923007061
23. Immunoblast - an overview | ScienceDirect Topics — www.sciencedirect.com — https://www.sciencedirect.com/topics/veterinary-science-and-veterinary-medicine/immunoblast
24. Brief Report Baseline SUVmax did not predict histological ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0006497120621140

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.